The EPS beat and financing are positive, but the expected CRL introduces regulatory uncertainty. Watch for FDA feedback on June 20 and details on NDA resubmission progress. The stock may trade on manufacturing resolution and upcoming ORCA-V2 trial data.
Price Chart
Executive Summary
Achieve Life Sciences reported Q1 2026 EPS of -$0.28, beating consensus of -$0.30 by 6.7%. The company also closed a $354M private placement, but faces an expected FDA Complete Response Letter due to manufacturing issues, with NDA resubmission targeted for Q4 2026 and launch in H1 2027.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.28 beat consensus of -$0.30 by 6.2%
- Cash and securities $29.3M at March 31, 2026, plus ~$168.6M net from private placement
- Closed $354M private placement with $180M upfront and $174M milestone warrants
- Expects FDA CRL by June 20, 2026 due to third-party manufacturing issues; NDA resubmission planned for Q4 2026
- U.S. commercial launch anticipated in H1 2027
- Appointed new CEO and expanded board; CCO departing in May 2026
Financial Impact
Cash position $29.3M + $168.6M net proceeds = ~$197.9M pro forma; net loss of $10.2M in Q1 2026
Risk Factors
- FDA CRL may delay approval beyond H1 2027 timeline
- Dilution from $354M financing (warrant exercises)
- Reliance on single product candidate with no approved therapy yet
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292668 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 3 | $7.24 $7.19 | ▼ −0.69% | ▼ −0.27% | $6.54 (−9.67%) |
Oct 1, 2026 25d ago | 8-K | $7.24 $7.01 | ▼ −3.18% | ▼ −3.85% | $6.54 (−9.67%) |
Aug 14, 2026 10w ago | 8-K | $7.50 $7.52 | ▼ −0.27% | ▼ −0.94% | $6.54 (+12.80%) |
Aug 11, 2026 10w ago | 8-K | $6.69 $7.25 | ▲ +8.37% | ▲ +7.67% | $6.54 (−2.24%) |
Aug 11, 2026 10w ago | Press Release | $6.77 $6.69 | ▲ +1.18% | ▲ +1.43% | $6.54 (+3.40%) |
Aug 7, 2026 11w ago | Institutional Cluster | $6.65 $6.67 | ▲ +0.30% | ▲ +0.33% | $6.54 (−1.65%) |
Jun 11, 2026 19w ago | Institutional Cluster | $5.52 $5.52 | · 0.00% | ▲ +0.54% | $6.54 (−18.48%) |
Jun 2, 2026 20w ago | 8-K | $5.03 $4.92 | ▼ −2.19% | ▼ −1.49% | $6.54 (+30.02%) |
May 22, 2026 22w ago | EFFECT | $4.69 $4.56 | ▲ +2.77% | ▲ +3.36% | $6.54 (−39.45%) |
May 19, 2026 22w ago | Press Release | $4.45 $4.57 | ▲ +2.70% | ▲ +1.66% | $6.54 (+46.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers